Valuation: Mesoblast Limited

Market Cap 2.29B 1.6B 1.42B 1.32B 1.2B 2.25B 152B 15.84B 6.22B 79.32B 6B 5.88B 253B P/E 2027 *
-74.6x
P/E 2028 * 18.7x
Enterprise Value 2.39B 1.67B 1.49B 1.38B 1.25B 2.35B 158B 16.56B 6.51B 82.93B 6.27B 6.14B 265B EV / Sales 2027 *
9.38x
EV / Sales 2028 * 5.84x
Free-Float
63.88%
Yield 2027 *
-
Yield 2028 * -
1 day+6.39%
1 week-5.90%
Current month-11.26%
1 month-12.09%
3 months-19.29%
6 months-18.59%
Current year-31.16%
1 week 1.74
Extreme 1.735
2.02
1 month 1.74
Extreme 1.735
2.29
Current year 1.74
Extreme 1.735
3.31
1 year 1.74
Extreme 1.735
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 23/03/2011
Director of Finance/CFO 59 17/11/2025
Chief Tech/Sci/R&D Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 69 01/01/2007
Director/Board Member 75 15/04/2013
Director/Board Member 79 06/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Free

Director

875,000 0.0674%
17/07/26 Exercice

Founder

1,885,334 0.1456%
17/07/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
+6.39%-5.90%-35.65%+406.08% 1.61B
+0.79%-6.16%+49.32%+74.50% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.85%+17.04%+59.17% 34B
-0.10%+0.52%+38.81%+8.34% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +3.04%+0.09%+43.13%+151.48% 37.74B
Weighted average by Cap. +2.80%+1.94%+49.83%+126.43%

Financials

2027 *2028 *
Net sales 255M 178M 159M 147M 133M 251M 16.9B 1.77B 694M 8.84B 669M 655M 28.21B 416M 291M 259M 240M 218M 409M 27.6B 2.88B 1.13B 14.44B 1.09B 1.07B 46.08B
Net income -26.28M -18.4M -16.37M -15.17M -13.75M -25.84M -1.74B -182M -71.53M -912M -69M -67.57M -2.91B 105M 73.27M 65.22M 60.44M 54.77M 103M 6.94B 725M 285M 3.63B 275M 269M 11.59B
Net Debt 104M 72.85M 64.85M 60.1M 54.46M 102M 6.9B 721M 283M 3.61B 273M 268M 11.52B 143M 100M 89.16M 82.64M 74.88M 141M 9.49B 992M 390M 4.97B 376M 368M 15.84B
Projected Income Statement - Annual - Mesoblast Limited
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
21/10/26 A$1.873 +6.39% 3,220,344
20/10/26 A$1.760 -0.56% 4,812,766
19/10/26 A$1.770 -11.06% 10,085,003
16/10/26 A$1.990 +2.58% 16,782,621
15/10/26 A$1.940 -2.51% 3,733,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Mesoblast Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.760AUD
Average target price
3.573AUD
Spread / Average Target
+103.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mesoblast Limited